© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Anteris Technologies Global Corp. (AVR) stock declined over -0.14%, trading at $7.24 on NASDAQ, down from the previous close of $7.25. The stock opened at $7.14, fluctuating between $6.94 and $7.36 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 15, 2026 | 7.14 | 7.36 | 6.94 | 7.24 | 1.03M |
| May 14, 2026 | 6.59 | 7.49 | 6.48 | 7.25 | 1.55M |
| May 13, 2026 | 6.45 | 6.69 | 6.30 | 6.53 | 710.72K |
| May 12, 2026 | 6.44 | 6.72 | 6.34 | 6.70 | 563.88K |
| May 11, 2026 | 6.65 | 6.75 | 6.43 | 6.51 | 749.88K |
| May 08, 2026 | 6.45 | 6.58 | 6.30 | 6.58 | 595.16K |
| May 07, 2026 | 6.37 | 6.54 | 6.29 | 6.51 | 487.51K |
| May 06, 2026 | 6.23 | 6.58 | 6.20 | 6.39 | 634.23K |
| May 05, 2026 | 6.22 | 6.36 | 6.15 | 6.19 | 407.76K |
| May 04, 2026 | 6.24 | 6.43 | 5.99 | 6.13 | 609.12K |
| Apr 30, 2026 | 5.80 | 6.16 | 5.71 | 6.15 | 747K |
| Apr 29, 2026 | 5.59 | 5.91 | 5.50 | 5.90 | 721.84K |
| Apr 28, 2026 | 5.73 | 6.06 | 5.51 | 5.68 | 1.23M |
| Apr 27, 2026 | 5.55 | 5.74 | 5.51 | 5.66 | 792.2K |
| Apr 23, 2026 | 5.70 | 5.76 | 5.49 | 5.53 | 400.78K |
| Apr 22, 2026 | 5.81 | 5.89 | 5.63 | 5.69 | 550.99K |
| Apr 21, 2026 | 5.90 | 5.90 | 5.64 | 5.70 | 420.32K |
| Apr 20, 2026 | 6.10 | 6.23 | 5.87 | 5.92 | 481.97K |
| Apr 17, 2026 | 6.06 | 6.13 | 5.95 | 6.07 | 930.13K |
| Apr 16, 2026 | 6.28 | 6.30 | 5.91 | 5.96 | 972.2K |
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
| Employees | 136 |
| Beta | 0.42 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | -0.918% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Medical - Devices |